Related Experiment Video
Updated: Sep 19, 2025
A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma DIPG
Published on: March 7, 2017
Nimotuzumab Combined With Chemoradiation Therapy in Newly Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma
Yanwei Liu1, Chao Liu2, Gang Wang3
1Department of Radiation Oncology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Purpose:
Diffuse intrinsic pontine glioma (DIPG) is a rare and fatal pediatric malignancy of the brainstem with a lack of effective therapeutic options. This study assesses the efficacy and safety of adding nimotuzumab to temozolomide (TMZ) chemoradiation therapy for newly diagnosed pediatric DIPG.
Methods And Materials:
We conducted an open-label, single-arm, prospective, multicenter study involving children aged 3-15 years with histologically or radiographically confirmed DIPG from April 3, 2021 to April 13, 2023. Nimotuzumab (150 mg/m2/wk) was administered concurrently with local radiation therapy (54 Gy/30 f) and TMZ (75 mg/m2/d) for 6 weeks, followed by adjuvant TMZ (150-200 mg/m2 for 5 consecutive days of a 28-day cycle for 6 cycles) and nimotuzumab (150 mg/m2 biweekly until to disease progression). The primary endpoint was objective response rate (ORR). The secondary endpoints were overall survival (OS), progression-free survival (PFS), and safety. Adverse events were summarized using descriptive statistics.
Results:
Of 48 enrolled patients, with a median age of 7 years (4-14), 28 (58.3%) were histologically confirmed, and 25 (89.3%) had H3K27M mutations. With a median follow-up of 26.5 months (95% CI, 14.6-not applicable), the ORR was 37.5%; the median OS and PFS were 10.5 (8.3-11.2) and 7.8 (5.1-8.4) months; and 1-year OS and PFS rates were 33.3% and 26.9%, respectively. Multivariate analysis showed that a partial response and no steroid use were associated with favorable OS. Distant metastasis was observed in 7 patients (14.6%). The most common grade ≥ 3 treatment-related adverse events were leukopenia (27.1%), lymphopenia (27.1%), and neutropenia (25.0%).
Conclusions:
Adding nimotuzumab to chemoradiation therapy is feasible, with ORR and survival rates favorably comparable with previous data in pediatric DIPG, despite not meeting the prespecified statistical significance for improved ORR compared with historical data. The overall safety profile was manageable, with no new safety concerns.
Insights
Adding nimotuzumab to temozolomide (TMZ) chemoradiation therapy for pediatric diffuse intrinsic pontine glioma (DIPG) showed manageable safety and comparable survival rates. Further research is needed to confirm improved objective response rates in this rare pediatric brain tumor.
Area of Science:
- Pediatric Oncology
- Neuro-oncology
- Clinical Cancer Research
Background:
- Diffuse intrinsic pontine glioma (DIPG) is a highly aggressive and fatal pediatric brainstem tumor.
- Current therapeutic options for DIPG are limited, highlighting the urgent need for novel treatment strategies.
- Nimotuzumab, an anti-EGFR antibody, is being investigated as a potential adjunct therapy.
Purpose of the Study:
- To evaluate the efficacy and safety of combining nimotuzumab with temozolomide (TMZ) chemoradiation for newly diagnosed pediatric DIPG.
- To assess the objective response rate (ORR), overall survival (OS), and progression-free survival (PFS) in patients receiving the combination therapy.
- To identify prognostic factors associated with improved outcomes in pediatric DIPG patients.
Main Methods:
- An open-label, single-arm, prospective, multicenter study was conducted in pediatric patients (3-15 years) with DIPG.
- Patients received concurrent nimotuzumab, radiation therapy, and TMZ, followed by adjuvant TMZ and nimotuzumab until disease progression.
- Primary endpoint was ORR; secondary endpoints included OS, PFS, and safety, with adverse events analyzed descriptively.
Main Results:
- The study enrolled 48 patients, with a median follow-up of 26.5 months.
- The objective response rate (ORR) was 37.5%, with median overall survival (OS) of 10.5 months and progression-free survival (PFS) of 7.8 months.
- Grade ≥3 treatment-related adverse events included leukopenia (27.1%), lymphopenia (27.1%), and neutropenia (25.0%); the safety profile was manageable.
Conclusions:
- Adding nimotuzumab to TMZ chemoradiation for pediatric DIPG is feasible and demonstrates manageable safety.
- The observed ORR and survival rates are comparable to historical data for DIPG, although statistical significance for improved ORR was not met.
- Partial response and absence of steroid use were associated with favorable overall survival, suggesting potential prognostic indicators.
